Show simple item record

dc.creatorSteiner, Robert A.
dc.creatorBremner, William J.
dc.creatorBagatell, Carrie J.
dc.identifierJ Clin Endocrinol Metab. 1991 Sep;73(3):465-9
dc.descriptionNo effective hormonal contraceptive has yet been devised for men. Through their suppressive effect on gonadotropin secretion, GnRH antagonists inhibit both testosterone (T) production and spermatogenesis in animals. Long term administration of an antagonist alone would result in androgen deficiency; this would cause unacceptable physiological and behavioral sequellae in men. Therefore, androgen replacement must be included in any GnRH antagonist regimen used in human male contraception. We tested the hypothesis that the combination of a GnRH antagonist plus T would suppress spermatogenesis in the male primate to azoospermic levels while maintaining normal serum T levels. We examined the effects of the GnRH antagonist Deterelix [N-Ac-DNal(2)1-DpCl-Phe2-DTrp3-DhArg(Et2)6 -DAla10-GnRH], alone and with simultaneous T replacement, on sperm production and serum T levels in adult male monkeys (n = 22). After 12 weeks of daily sc antagonist injection, all animals that received antagonist alone (n = 5) and those that 750 micrograms/ antagonist plus T (n = 5) were azoospermic. After 16 weeks, four of five animals that received 250 micrograms/ antagonist plus T became azoospermic. Control animals (n = 7) received daily injections of vehicle; sperm counts increased somewhat during the study period in that group. Castrate range T levels were achieved in animals receiving antagonist alone. T levels in the groups that received T supplementation and in the control group were in the normal male range throughout the treatment period. Sperm counts returned to the pretreatment range in all animals during the recovery period. We conclude that the combination of a GnRH antagonist plus T can induce azoospermia reversibly in this nonhuman primates species, and that a similar combination may be an effective contraceptive regimen in men. The GnRH antagonist alone may be an effective treatment for androgen-dependent neoplasia.
dc.publisherEndocrine Society
dc.subject5-alpha reductase inhibitors
dc.subjectklinefelter's syndrome
dc.subjectreifenstein's syndrome
dc.subjectmale contraception
dc.subjectResearch Support, U.S. Gov't, Non-P.H.S.
dc.subjectSpermatogenesis, drug effects
dc.subjectTestis, cytology, drug effects
dc.subjectResearch Support, U.S. Gov't, P.H.S.
dc.subjectContraceptive Agents, Male, pharmacology
dc.subjectTestosterone, blood, pharmacology
dc.subjectSpermatozoa, drug effects
dc.subjectGonadorelin, analogs & derivatives, antagonists & inhibitors, pharmacology
dc.subjectMacaca fascicularis
dc.subjectDrug Therapy, Combination
dc.subjectBody Weight, drug effects
dc.titleGonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record